Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Push Health vs Ro

Ro costs $801 less a month.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
Push Health logo

Push Health

5.6
★★★☆☆2.8/5

Best for: semaglutide from $950/month

Visit Push Health →
VS
Ro logo

Ro

6.7
★★★☆☆3.4/5

Best for: knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC

Visit Ro →

If you are choosing between Push Health and Ro, the first difference is cost: Ro is $801 a month cheaper at the entry price. Ro leads our six-part score, 6.7 to 5.6.

Push Health vs Ro price

Ro is the cheaper way in: $149 a month against $950 a month at Push Health. That is $801 less each month (84% lower), or about $9,612 over a year of treatment.

Medications and formats

Push Health and Ro do not overlap on medication; only Push Health lists semaglutide; only Ro lists orforglipron.

On format they match: each offers brand-name pens.

Where each one treats patients

Neither Push Health nor Ro publishes the states it serves, so enter your state at the very start of each sign-up.

Pricing

Push Health

PreliminaryBrand-name
$950/mo
semaglutide

Ozempic / brand

Ro

Foundayo (lowest dose, cash pay)Brand-name
$149/mo
orforglipron

Additional membership fees apply

What each price covers

Ro's price also covers the clinician visit, lab work and coaching, which Push Health does not claim.

Push Health does not say what its price includes.

Ro is silent on shipping.

Push Health

Inclusions not disclosed.

Ro

Covered by the monthly price

Medication

Charged on top

Clinician visits

In the price

Shipping

Not stated

Lab work

In the price

Coaching

In the price

Where each one scores higher

Overall, Ro scores 6.7 and Push Health 5.6 out of 10.

Push Health is stronger on effectiveness (9.0 vs 8.0).

Ro is stronger on user experience (8.0 vs 3.0), trust & safety (8.0 vs 4.0) and support (5.5 vs 5.0).

Value and accessibility are within half a point.

How we score

Push Health

5.6/10

Overall

Ro

6.7/10

Value25%

5.3A
vs
B
5.0

Effectiveness25%

9.0A
vs
B
8.0

User Experience15%

3.0A
vs
B
8.0

Trust & Safety15%

4.0A
vs
B
8.0

Accessibility10%

5.0A
vs
B
5.0

Support10%

5.0A
vs
B
5.5

FDA warning letters

Neither Push Health nor Ro has an FDA warning letter on record with us.

Features & Coverage

FeaturePush HealthRo
Starting Price$950/mo✓$149/mo
Features5 features✓7 features
States AvailableNot disclosedNot disclosed
Compounded——
Brand Name✓ Yes✓ Yes
FSA/HSA Accepted——
FDA Warning LettersNoneNone

About Push Health

A 55,000+ pharmacy network sits behind Push Health, which writes brand-name GLP-1 prescriptions, Mounjaro, Zepbound, and Ozempic, and routes them through it. The platform is a large US telehealth operation and holds LegitScript certification.

Read our full Push Health review →

About Ro

Foundayo (orforglipron), the new oral GLP-1 from Eli Lilly, joined Ro on April 9 2026 at $149/month for the lowest dose, membership on top. Beside it sit compounded semaglutide and the brand-name pair, Zepbound and Wegovy. No obesity care formulary in the category is more comprehensive. In the US, only a handful of direct-to-patient telehealth companies are larger.

Read our full Ro review →

Pros & Cons

Push Health

What we like

  • Semaglutide costs $950 a month, close to the $990 median for brand-name semaglutide across the sellers we compare
  • We found no FDA warning letters issued to Push Health

Watch-outs

  • You only see a price after finishing the medical intake, so you cannot compare costs before sharing health information
  • Confirm it serves your state before you start the intake
  • Ask which pharmacy fills the prescription before you pay, so you can check its license

Ro

What we like

  • Orforglipron costs $149 a month, close to the $149 median for brand-name orforglipron across the sellers we compare
  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes clinician visits, lab work and coaching
  • Names Roman Health Pharmacy LLC as the pharmacy that fills its prescriptions, which most sellers do not
  • We found no FDA warning letters issued to Ro

Watch-outs

  • Not included in the monthly price: medication
  • Confirm it serves your state before you start the intake

Our Verdict

Winner: Ro

Ro wins this one, 6.7 to 5.6, above all for knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC. It also costs $801 less each month than Push Health. Push Health fits better if semaglutide from $950/month is your priority.

Choose Push Health if…

You want semaglutide from $950/month and an opening price near $950 a month.

Choose Ro if…

You want knowing which pharmacy fills the vial: it names Roman Health Pharmacy LLC and an opening price near $149 a month.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.4

Collective

Flat any-dose pricing, if you can absorb a $199 annual membership on top

8.6

Found

Tirzepatide at $169/month, 37% below the typical price

7.6

Breeze Meds

Knowing which pharmacy fills the vial: it names Belmar Pharmacy

Push Health vs Ro: FAQ

Ro. It starts at $149 a month; Push Health starts at $950 a month, $801 more per month.
No. Push Health lists semaglutide; Ro lists orforglipron.
Push Health does not publish where it ships; Ro does not publish where it ships. Confirm your state before paying.
Only Ro includes the clinician visit, lab work and coaching.
Push Health has none. Ro has none.
No. Neither Push Health nor Ro pays us anything.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.